Three semaglutide trials report less heavy drinking or craving, while tirzepatide reduced alcohol reward in rodents. Here is what researchers know.
Read the report
GLP-1 withdrawal trials show common weight regain. New 2026 evidence tests continued and reduced-dose maintenance—and exposes the questions left open.
A flat scale or returning appetite can make dose escalation feel obvious. The evidence says to check the trend, waist, strength, adherence and side effects first.
How U.S. GLP-1 prices and insurance denials drive patients toward cash pay, compounding and the grey market—and what each pathway proves.
GH-releasing peptides amplify feedback-regulated signaling instead of activating androgen receptors. Here is why they may carry less risk than steroids.
Tesamorelin has FDA approval and visceral-fat trial data. CJC-1295 DAC and the no-DAC form stimulate growth-hormone signaling through different research paths.
Research Pep News follows more than announcements. We track the scientific questions, regulatory decisions, market forces, and public narratives that determine what a peptide story actually means.